LONDON, December 12, 2017 /PRNewswire/ --
The Global Chronic Kidney Disease (CKD) Drugs market reached $12.2bn in 2016 and is expected to grow at a CAGR of 3.9% in the first half of the forecast period. The market is dominated by calcium channel blockers and ACE inhibitors.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 171-page report you will receive 85 tables and 93 figures - all unavailable elsewhere.
The 171-page report provides clear detailed insight into the Global Chronic Kidney Disease (CKD) Drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Chronic Kidney Disease (CKD) Drugs market forecasts from 2018-2028
• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by drug class: - ACE inhibitors - Angiotensin-II receptor blockers - Calcium channel blockers - Beta blockers: BREVIBLOC, Bystolic - Erythropoiesis-stimulating agents (ESAs) - Diuretics - Others
This report provides a SWOT Analysis for each drug class.
• This report provides revenue forecast for these leading drugs: - Aceon - Lisinopril - Losartan - AVAPRO - Twynsta - BREVIBLOC - Bystolic - Mircera - Epoetin Alfa BS - Natrilix SR - Spironolactone - Urief - AURYXIA
• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by distribution channel: - Retail Pharmacies - Hospital Pharmacies - Online Pharmacies - Others
• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by regional and national market: - North America: US and Canada - Europe: Germany, the UK, France, Spain, Italy, Rest of Europe - Asia-Pacific: Japan, China, India, Rest of Asia-Pacific - Latin America: Brazil, Mexico, Rest of Latin America - Middle East & Africa: Saudi Arabia, South of Africa, Rest of MEA
Each regional market is further broken down by drug class and distribution channel.
• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the Global Chronic Kidney Disease (CKD) Drugs market: - Pfizer, Inc. - Amgen - Roche - GlaxoSmithKline (GSK) - Allergan - AbbVie - Kissei Pharmaceutical Co., Ltd.
Buy our report today Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website:
https://www.visiongain.com/Report/2073/Global-Chronic-Kidney-Disease-(CKD)-Drugs-Market-Forecast-2018-2028
List of Companies Mentioned in the Report
Abbott Laboratories
AbbVie, Inc.
Allergan plc
Amgen, Inc.
AstraZeneca Pharmaceuticals LP
Bausch & Lomb Incorporated
Baxter International Inc.
Bayer
Boehringer Ingelheim GmbH
Eisai Co., Ltd
Emory Healthcare
F. Hoffmann-La Roche Ltd
Fresenius
Galenica
GlaxoSmithKline plc
Hospira
Instituto Terapeutico Delta Ltd
Japan Chemical Research Pharmaceuticals Co., Ltd.
Keryx Biopharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Lupin Laboratories Ltd.
Manus Aktteva Biopharma LLP.
Morepen Laboratories Ltd.
Novartis International AG
ObsEva
Pfizer, Inc.
Sanofi S.A.
Sanofi-aventis U.S. LLC
Serdia Pharmaceuticals Pvt. Ltd.
Teva Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals International, Inc.
Validus Pharmaceuticals, Inc.
Vifor Fresenius Medical Care Renal Pharma
Zydus Cadila
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
Advertisement
ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Advertisement
The Global Chronic Kidney Disease (CKD) Drugs market reached $12.2bn in 2016 and is expected to grow at a CAGR of 3.9% in the first half of the forecast period. The market is dominated by calcium channel blockers and ACE inhibitors.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 171-page report you will receive 85 tables and 93 figures - all unavailable elsewhere.
The 171-page report provides clear detailed insight into the Global Chronic Kidney Disease (CKD) Drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Chronic Kidney Disease (CKD) Drugs market forecasts from 2018-2028
• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by drug class: - ACE inhibitors - Angiotensin-II receptor blockers - Calcium channel blockers - Beta blockers: BREVIBLOC, Bystolic - Erythropoiesis-stimulating agents (ESAs) - Diuretics - Others
This report provides a SWOT Analysis for each drug class.
• This report provides revenue forecast for these leading drugs: - Aceon - Lisinopril - Losartan - AVAPRO - Twynsta - BREVIBLOC - Bystolic - Mircera - Epoetin Alfa BS - Natrilix SR - Spironolactone - Urief - AURYXIA
• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by distribution channel: - Retail Pharmacies - Hospital Pharmacies - Online Pharmacies - Others
• This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by regional and national market: - North America: US and Canada - Europe: Germany, the UK, France, Spain, Italy, Rest of Europe - Asia-Pacific: Japan, China, India, Rest of Asia-Pacific - Latin America: Brazil, Mexico, Rest of Latin America - Middle East & Africa: Saudi Arabia, South of Africa, Rest of MEA
Each regional market is further broken down by drug class and distribution channel.
• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the Global Chronic Kidney Disease (CKD) Drugs market: - Pfizer, Inc. - Amgen - Roche - GlaxoSmithKline (GSK) - Allergan - AbbVie - Kissei Pharmaceutical Co., Ltd.
Buy our report today Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028: ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretic, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website:
https://www.visiongain.com/Report/2073/Global-Chronic-Kidney-Disease-(CKD)-Drugs-Market-Forecast-2018-2028
List of Companies Mentioned in the Report
Abbott Laboratories
AbbVie, Inc.
Allergan plc
Amgen, Inc.
AstraZeneca Pharmaceuticals LP
Bausch & Lomb Incorporated
Baxter International Inc.
Bayer
Boehringer Ingelheim GmbH
Eisai Co., Ltd
Emory Healthcare
F. Hoffmann-La Roche Ltd
Fresenius
Galenica
GlaxoSmithKline plc
Hospira
Instituto Terapeutico Delta Ltd
Japan Chemical Research Pharmaceuticals Co., Ltd.
Keryx Biopharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Lupin Laboratories Ltd.
Manus Aktteva Biopharma LLP.
Morepen Laboratories Ltd.
Novartis International AG
ObsEva
Pfizer, Inc.
Sanofi S.A.
Sanofi-aventis U.S. LLC
Serdia Pharmaceuticals Pvt. Ltd.
Teva Pharmaceutical Industries Ltd.
Valeant Pharmaceuticals International, Inc.
Validus Pharmaceuticals, Inc.
Vifor Fresenius Medical Care Renal Pharma
Zydus Cadila
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
